Invention of MK-0616 – Merck’s Macrocyclic Peptide Oral PCSK9 Inhibitor
Time: 8:30 am
day: Conference Day Two
Details:
- Highlighting the need for new modalities to drug challenging targets
- Elevating cyclic peptides as privileged scaffolds and a potential alternative to small molecules and large biopharmaceuticals
- Integrating various capabilities, including mRNA display and structure-based drug design, into drug discovery
